Navigation Links
Coalition for the Advancement of Medical Research Releases New White Paper, 'Catalyst for Cures: Embryonic Stem Cell Research'
Date:1/14/2009

- National Poll Reveals Three-Quarters of Americans Want President-Elect Obama to Deliver on Campaign Commitment to Lift Restrictions on Embryonic Stem Cell Research -

WASHINGTON, Jan. 14 /PRNewswire-USNewswire/ -- The Coalition for the Advancement of Medical Research (CAMR) today released a white paper, Catalyst For Cures: Embryonic Stem Cell Research, which outlines the views of nine of the nation's leading scientists on the promises and challenges of embryonic stem cell research. In support for the scientific community's call for reversal of the current restrictions on funding for stem cell research, the group also released the results of a national poll conducted this month for CAMR by Opinion Research Corporation indicating that nearly three-quarters (73%) of Americans believe that President-elect Obama should keep his pledge to lift existing federal restrictions on embryonic stem cell research.

Marking the 10th anniversary of the announcements by James Thomson and John Gearhart that each had successfully grown the first human pluripotent stem cell lines in culture, the White Paper proclaims that "with the knowledge gained in the past decade, stem cell research is more promising than ever."

Despite limited funding, scientists have made great strides in using these primary cells to understand what goes wrong in disease and have begun devising promising new therapies for devastating conditions, such as heart disease, spinal cord injury, and diabetes. Conversations with some of the nation's top stem cell researchers -- in academia and industry -- make clear that, with removal of limits on Federal funding, embryonic stem cell research will fulfill its promise in broader ways than originally anticipated.

"It's time for the federal government to support the broad range of stem cell research so that the greatest public benefit can be achieved on the shoulders of the last 10 years' accomplishments," said Amy Comstock Rick, president of CAMR. "We are hopeful that President-elect Obama will deliver on his campaign commitment to lift the current restrictions, and allow scientists to deliver on the promise of embryonic stem cell research."

Catalyst for Cures: Embryonic Stem Cell Research shares experts' viewpoints and assessments of embryonic stem cell research to date, and takes a bold look at where this research might lead in the coming years. Some highlights include:

"I'd be very surprised if, during the course of my scientific career, the next 20 years, we don't have much better therapies for Parkinson's disease, based on the fact that we have these hESC-derived tissues in culture," says James Thomson.

Many scientists have been studying adult stem cells and learning more about their utility and their limitations. So far, adult stem cells have only successfully been used in a very narrow area: blood system reconstitution, including bone marrow transplant, umbilical cord transplant, and peripheral blood transplant. "The argument that there are 60 to 70 diseases that can be cured with adult stem cells was never credible," says Sean Morrison, University of Michigan.

Biotech firms are revving up, focused on toxicity screening and drug development. A few are aggressively pursuing hES cell-based therapies. Big Pharma is also beginning to invest in stem cells. "Embryonic stem cells are a source of cells for predictive toxicology and drug discovery," says consultant and former Novocell executive Melissa Carpenter.

The Paper concludes that, "scientists see great promise in efforts to improve therapies for diabetes, Parkinson's disease, macular degeneration, cancer, spinal cord injuries, and heart disease. The time for removal of restrictions, expanded support, and implementation of relevant oversight guidelines is now."

The full text of Catalyst for Cures: Embryonic Stem Cell Research is available on the CAMR web site at www.camradvocacy.com.

The following researchers and thought leaders contributed to this white paper:

Melissa K. Carpenter, Ph.D., former Vice President of Research and Development at Novocell Inc., and Director of Stem Cell Biology at Geron Corporation; George Daley, M.D., Ph.D., Harvard Medical School; Kevin C. Eggan, Ph.D., Principal Faculty, Harvard Stem Cell Institute; John P. Gearhart, M.D., Director, Institute for Regenerative Medicine at University of Pennsylvania; Ole Isacson, Dr.Med.Sci., Professor of Neurology, Harvard Medical School; Hans Keirstead, Ph.D., Associate Professor, Anatomy and Neurobiology at University of California, Irvine; Douglas A. Melton, Ph.D., Co-director of the Harvard Stem Cell Institute; Sean J. Morrison, Ph.D., Director, University of Michigan Center for Stem Cell Biology; and James Thomson, V.M.D., Ph.D., Director of Regenerative Biology at University of Wisconsin School of Medicine and Public Health.

About the Coalition for the Advancement of Medical Research

The Coalition for the Advancement of Medical Research (CAMR) -- the leading pro-cures coalition -- is comprised of nationally recognized patient organizations, universities, scientific societies, foundations, and individuals with life-threatening illnesses and disorders, advocating for the advancement of breakthrough research and technologies in regenerative medicine -- including stem cell research -- to cure disease and alleviate suffering. For more information on CAMR, visit www.camradvocacy.org.


'/>"/>
SOURCE Coalition for the Advancement of Medical Research
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Joins the Personalized Medicine Coalition (PMC)
2. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
3. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
4. FrontPath Health Coalition To Lead Community-wide Group in Pilot Program
5. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
6. Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story
7. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
8. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
9. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
10. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
11. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... ... Park Systems , a leader in Atomic Force Microscopy (AFM) since ... attendees and Park customers on Feb. 27, 2017 from 12-2pm at Morton’s The Steakhouse ... The luncheon will feature a talk on Automated AFM for Small-Scale and Large-Scale Surface ...
(Date:2/22/2017)... CINCINNATI , Feb. 22, 2017 Scientists ... drives inflammation and organ damage in Gaucher and maybe ... fewer risks and lower costs than current therapies. ... Children,s Hospital Medical Center , which also included investigators ... , report their data Feb. 22. The study ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... of precision treatments for neurodegenerative diseases, today announced it has issued a scientific ... This is one of a series of commentaries from ProMIS’s scientific team offering ...
(Date:2/22/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... announce the launch of a new scholarship for young scientists seeking a degree in ... is open to all high school seniors, 17 years or older; as well as ...
Breaking Biology Technology:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):